N/A N=18 Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis
Eosinophilic Gastroenteritis
Primary: Percent of Participants in Complete Histologic Remission — 100 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=93 A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
Eosinophilic Duodenitis · Eosinophilic Gastroenteritis
Primary: Proportion of Tissue Eosinophil Responders at Week 24 — 38; 2 Participants — p=<0.0001
Phase 2 N=41 Dupilumab in Eosinophilic Gastritis
Eosinophilic Gastritis · Eosinophilic Gastroenteritis
Primary: Relative Change of Peak Eosinophil Counts in the Stomach — -50.28; -3.54 Eosinophil per HPF (EOS/HPF)
Phase 2 N=42 Topical Steroid Treatment for Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74
Phase 4 N=21 Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Esophageal Eosinophilia (Number of Eosinophils in the Esophagus) — 5.3 eosinophils/high power field
N/A N=24 Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)
Eosinophilic Esophagitis
Primary: Percentage of Histologic Responders — 21 percentage of participants
Phase 2 N=47 Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Absolute Change From Baseline in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score at Week 10 — -1.3; -3.0 Score on a Scale — p=0.0304
N/A N=50 Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis
Suspected Eosinophilic Esophagitis
Primary: Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) — 69; 79 Percent Change
Phase 3 N=51 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Eosinophilic Esophagitis · Gastroesophageal Reflux Disease · EE
Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00
Phase 2 N=30 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
Esophagitis
Primary: Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and Post-treatment and Between Both Groups — 0.6; -7.5 perecentage of eos per…
Phase 3 N=63 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids
Eosinophilic Esophagitis · Eosinophilic Gastrointestinal Disorders (EGIDs)
Primary: Change From Baseline in Pediatric EoE Symptom Score Version 2.0 (PEESS V2.0) at 12 Weeks — -14.3; -21.6 units on a scale — p=0.04
Phase 3 N=318 A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
Eosinophilic Esophagitis (EoE)
Primary: Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16) — 1; 113; 104; 100 Participants — p=<0.001
Phase 2 N=32 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Improvement of Espohageal Eosinophilia — 13; 0 Participants
N/A N=42 Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants Who Responded — 7; 4 participants
N/A N=8 Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Sensitivity of Patch Testing — 1 Participants
N/A N=30 Mucosal Impedance and Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms
N/A N=25 Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Tissue Eosinophil Counts — 89; 11 # of eosinophils per high-power field
Phase 3 N=102 Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis (EoE)
Primary: Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at…
Phase 3 N=81 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24…
Phase 4 N=16 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Peak Esophageal Eosinophil Count — 57.3; 71.3 Peak # of eosinophils counted per field
N/A N=22 Cytosponge and Dietary Therapy in EoE
Eosinophilic Esophagitis
Primary: Histological Remission by Sponge Cytology — 13 Participants
Phase 3 N=181 A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Eosinophilic Gastritis · Eosinophilic Duodenitis
Primary: Proportion of Tissue Eosinophil Responders at Week 24 — 77; 4 Participants — p=<0.0001
Phase 2 N=65 A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Eosinophilic Gastritis · Eosinophilic Gastroenteritis
Primary: Percent Change in the Number of Eosinophils Per High Power Field in Gastric or Duodenal Mucosa From Baseline — -79; -92; -86; 9 Percentage of Change — p=<0.001
Phase 2 N=66 Mepo for Eosinophilic Esophagitis (EoE) Study
EoE · Eosinophilic Esophagitis
Primary: Mean Change in Dysphagia Score — 15.4; 8.3 score on a scale — p=0.14
Phase 4 N=129 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Post-Treatment Maximum Eosinophil Count (Aim 1) — 14.7; 20.9 eosinophils per high-power field — p=0.31
Phase 2 N=82 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis
Eosinophilic Esophagitis (EoE)
Primary: Percent of Participants Who Responded to Therapy — 5.6; 11.8; 52.6; 47.1 percentage of participants — p=0.5282
Phase 3 N=26 Benralizumab for Eosinophilic Gastritis (BEGS)
Eosinophilic Gastritis or Gastroenteritis
Primary: Percent of Patients in Histological Remission (<30 Eos/Hpf) — 77; 8 percentage of participants — p=0.0001
Phase 3 N=159 An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Eosinophilic Gastritis · Eosinophilic Duodenitis
Primary: The Safety and Tolerability of Lirentelimab by Evaluating Adverse Events Assessed Using the CTCAE Version 5.0 — 66; 75; 33; 29 Participants
Phase 2 N=308 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) — 10; 19; 14; 16 Participants — p=0.001
Phase 2 N=58 An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Eosinophilic Gastritis · Eosinophilic Gastroenteritis · Eosinophilic Duodenitis
Primary: The Safety and Tolerability of AK002 by Evaluating Adverse Events Assessed Using the CTCAE Version 4.03 — 21; 35; 15; 22 Participants